11/20
01:16 pm
arwr
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.
Low
Report
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.
11/18
07:45 am
arwr
Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran [Yahoo! Finance]
Low
Report
Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran [Yahoo! Finance]
11/18
07:33 am
arwr
Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome [Yahoo! Finance]
Low
Report
Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome [Yahoo! Finance]
11/18
07:31 am
arwr
Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome
Low
Report
Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome
11/18
07:30 am
arwr
Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran
Low
Report
Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran
11/13
12:08 am
arwr
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) was upgraded by analysts at StockNews.com to a "sell" rating.
Low
Report
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) was upgraded by analysts at StockNews.com to a "sell" rating.
11/5
07:30 am
arwr
Arrowhead Pharmaceuticals to Webcast 2024 Fiscal Year End Results
Low
Report
Arrowhead Pharmaceuticals to Webcast 2024 Fiscal Year End Results
11/4
07:30 am
arwr
Arrowhead Pharmaceuticals to Participate in Upcoming November 2024 Conferences
Medium
Report
Arrowhead Pharmaceuticals to Participate in Upcoming November 2024 Conferences
11/1
07:30 am
arwr
Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, ‘We’ll Get There Soon,’ to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome
Low
Report
Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, ‘We’ll Get There Soon,’ to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome
10/17
11:10 pm
arwr
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) was upgraded by analysts at StockNews.com to a "sell" rating.
Low
Report
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) was upgraded by analysts at StockNews.com to a "sell" rating.
10/14
04:30 pm
arwr
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Low
Report
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
10/11
03:42 pm
arwr
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.
Low
Report
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.
10/8
11:36 am
arwr
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $62.00 price target on the stock.
Low
Report
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $62.00 price target on the stock.
9/26
10:15 am
arwr
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $42.00 price target on the stock.
Low
Report
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $42.00 price target on the stock.
9/24
07:49 am
arwr
Arrowhead Pharmaceuticals seeks approval for obesity treatment trial in New Zealand [Yahoo! Finance]
Low
Report
Arrowhead Pharmaceuticals seeks approval for obesity treatment trial in New Zealand [Yahoo! Finance]
9/23
12:34 pm
arwr
With 73% ownership of the shares, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is heavily dominated by institutional owners [Yahoo! Finance]
Low
Report
With 73% ownership of the shares, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is heavily dominated by institutional owners [Yahoo! Finance]
9/23
07:30 am
arwr
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity
Medium
Report
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity
9/16
12:03 am
arwr
Trailhead Biosystems Announces Joshua Snow as Chief Commercial Officer [Yahoo! Finance]
Medium
Report
Trailhead Biosystems Announces Joshua Snow as Chief Commercial Officer [Yahoo! Finance]
9/11
06:28 am
arwr
FDA grants breakthrough therapy status to Arrowhead's plozasiran [Yahoo! Finance]
Low
Report
FDA grants breakthrough therapy status to Arrowhead's plozasiran [Yahoo! Finance]
9/10
03:24 pm
arwr
ARWR: PALISADE Phase 3 Results Published in NEJM… [Yahoo! Finance]
Low
Report
ARWR: PALISADE Phase 3 Results Published in NEJM… [Yahoo! Finance]
9/10
07:30 am
arwr
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran
Low
Report
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran
9/9
01:03 pm
arwr
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Low
Report
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
9/3
02:08 pm
arwr
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.
Low
Report
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.
9/3
10:56 am
arwr
Arrowhead Pharmaceuticals Stock Climbs on Plans To Seek FDA Approval for New Drug [Yahoo! Finance]
Medium
Report
Arrowhead Pharmaceuticals Stock Climbs on Plans To Seek FDA Approval for New Drug [Yahoo! Finance]
9/2
06:45 am
arwr
Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome [Yahoo! Finance]
Low
Report
Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome [Yahoo! Finance]